InvestorsHub Logo
Followers 12
Posts 764
Boards Moderated 0
Alias Born 06/19/2013

Re: None

Thursday, 10/22/2015 12:26:52 PM

Thursday, October 22, 2015 12:26:52 PM

Post# of 346183
Guys, what about a designation? Recall Peregrine got FTD at about the same time as the start of SUNRISE. Now there's a lot of new information, including from SUNRISE, about bavituximab's MOA. What are the chances of getting a designation, be it FTD or something else, for any of the new trials:

1. Paclitaxel/Docetaxel + B, HER2- MBC, to be started before YE2015

2. Durvalumab + B in solid tumors, in 2016

3. Durvalumab + B in sq+non-sq NSCLC, in 2016

4. HER2- early stage BC, under review

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News